Corvus Pharmaceuticals Receives $75,000,000 Series B Funding

  • Feed Type
  • Date
    9/30/2015
  • Company Name
    Corvus Pharmaceuticals
  • Mailing Address
    863 Mitten Road Burlingame, CA 94010 USA
  • Company Description
    Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer.
  • Website
    http://www.corvuspharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $75,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used to expand the company’s research and development programs of multiple small molecule and antibody agents in immuno-oncology, including the initiation of a multicenter Phase 1B trial, which is expected to begin in the first quarter of 2016.
  • M&A Terms
  • Venture Investor
    Rock Springs Capital
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    BlackRock
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    venBio
  • Venture Investor
    Cowen Capital Partners
  • Venture Investor
    OrbiMed
  • Venture Investor
    Novo Ventures
  • Venture Investor
    Adams Street Partners
  • Venture Investor
    Undisclosed